256 related articles for article (PubMed ID: 12433352)
1. [Surveillance for antimicrobial resistance: VIRA Study].
Picazo JJ; Betriu C; Rodríguez-Avial I; Azahares E; Ali Sánchez B;
Enferm Infecc Microbiol Clin; 2002 Dec; 20(10):503-10. PubMed ID: 12433352
[TBL] [Abstract][Full Text] [Related]
2. [Antimicrobial resistance surveillance: VIRA STUDY 2006].
Picazo JJ; Betriu C; Rodríguez-Avial I; Culebras E; Gómez M; López F;
Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):617-28. PubMed ID: 17194387
[TBL] [Abstract][Full Text] [Related]
3. [Surveillance of antimicrobial resistance: VIRA study 2004].
Picazo JJ; Betriu C; Rodríguez-Avial I; Culebras E; Gómez M;
Enferm Infecc Microbiol Clin; 2004 Nov; 22(9):517-25. PubMed ID: 15511392
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.
Sweeney MT; Zurenko GE
Antimicrob Agents Chemother; 2003 Jun; 47(6):1902-6. PubMed ID: 12760865
[TBL] [Abstract][Full Text] [Related]
5. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
Decousser JW; Woerther PL; Soussy CJ; Fines-Guyon M; Dowzicky MJ
Antimicrob Resist Infect Control; 2018; 7():68. PubMed ID: 29876099
[TBL] [Abstract][Full Text] [Related]
6. [Antibiotic resistance of Gram-positive cocci isolated in 2008].
Dorobăţ OM; Bădicuţ I; Tălăpan D; Tenea C; Rafila A
Bacteriol Virusol Parazitol Epidemiol; 2010; 55(2):83-92. PubMed ID: 21553473
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of the pathogenic characteristics of 162 severely burned patients with bloodstream infection].
Gong YL; Yang ZC; Yin SP; Liu MX; Zhang C; Luo XQ; Peng YZ
Zhonghua Shao Shang Za Zhi; 2016 Sep; 32(9):529-35. PubMed ID: 27647068
[TBL] [Abstract][Full Text] [Related]
8. Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases.
Ishikawa K; Hamasuna R; Uehara S; Yasuda M; Yamamoto S; Hayami H; Takahashi S; Matsumoto T; Minamitani S; Kadota J; Iwata S; Kaku M; Watanabe A; Sunakawa K; Sato J; Hanaki H; Tsukamoto T; Kiyota H; Egawa S; Deguchi T; Matsumoto M; Tanaka K; Arakawa S; Fujisawa M; Kumon H; Kobayashi K; Matsubara A; Wakeda H; Amemoto Y; Onodera S; Goto H; Komeda H; Yamashita M; Takenaka T; Fujimoto Y; Tsugawa M; Takahashi Y; Maeda H; Onishi H; Ishitoya S; Nishimura K; Mitsumori K; Ito T; Togo Y; Nakamura I; Ito N; Kanamaru S; Hirose T; Muranaka T; Yamada D; Ishihara S; Oka H; Inatomi H; Matsui T; Kobuke M; Kunishima Y; Kimura T; Ichikawa T; Kagara I; Matsukawa M; Takahashi K; Mita K; Kato M; Okumura K; Kawanishi H; Hashimura T; Aoyama T; Shigeta M; Koda S; Taguchi K; Matsuda Y
J Infect Chemother; 2015 Sep; 21(9):623-33. PubMed ID: 26166322
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic Resistance Among Ocular Pathogens in the United States: Five-Year Results From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study.
Asbell PA; Sanfilippo CM; Pillar CM; DeCory HH; Sahm DF; Morris TW
JAMA Ophthalmol; 2015 Dec; 133(12):1445-54. PubMed ID: 26502312
[TBL] [Abstract][Full Text] [Related]
10. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1997)].
Ikemoto H; Ito C; Yoshida T; Watanabe K; Mori T; Ohno I; Okada S; Igari J; Arakawa M; Igarashi K; Oguri T; Okada M; Ozaki K; Terai T; Aoki N; Inoue H; Nakadate T; Kitamura N; Sekine O; Suzuki Y; Ando M; Suga M; Sato K; Nakata K; Kusano N
Jpn J Antibiot; 1999 May; 52(5):353-97. PubMed ID: 10480048
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of quinupristin/dalfopristin and eight other antimicrobial agents against 360 clinical isolates from Korea.
Hwang SH; Kim MN; Pai CH; Huh DH; Shin WS
Yonsei Med J; 2000 Oct; 41(5):563-9. PubMed ID: 11079615
[TBL] [Abstract][Full Text] [Related]
12. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).
Pfaller MA; Huband MD; Streit JM; Flamm RK; Sader HS
Int J Antimicrob Agents; 2018 Jun; 51(6):848-853. PubMed ID: 29410368
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008).
Zhanel GG; DeCorby M; Adam H; Mulvey MR; McCracken M; Lagacé-Wiens P; Nichol KA; Wierzbowski A; Baudry PJ; Tailor F; Karlowsky JA; Walkty A; Schweizer F; Johnson J; ; Hoban DJ
Antimicrob Agents Chemother; 2010 Nov; 54(11):4684-93. PubMed ID: 20805395
[TBL] [Abstract][Full Text] [Related]
14. [Bacterial strains isolated from systemic infections and reported for evaluation and antibiotic resistance surveillance by the "Dr. Victor Babeş" Clinical Hospital for Infectious and Tropical Diseases, Bucharest].
Nica M; Biolan T; Dascălu A; Mozes E; Toderan A; Calistru P; Ceauşu E
Bacteriol Virusol Parazitol Epidemiol; 2010; 55(2):161-8. PubMed ID: 21553481
[TBL] [Abstract][Full Text] [Related]
15. [Bloodstream infections in southwestern China: 2012 Whire Union report on bacterial susceptibility to antibiotics].
Huang YC; Xie Y; Chen ZX; Liu B; Fei Y; Du Y; Shan B; Kang M
Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Jan; 46(1):75-81. PubMed ID: 25993745
[TBL] [Abstract][Full Text] [Related]
16. [In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,866 clinical isolates obtained from 72 centers in 2010].
Yamaguchi K; Ohno A; Ishii Y; Tateda K; Iwata M;
Jpn J Antibiot; 2012 Jun; 65(3):181-206. PubMed ID: 23173294
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.
Chamberland S; Blais J; Hoang M; Dinh C; Cotter D; Bond E; Gannon C; Park C; Malouin F; Dudley MN
Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805
[TBL] [Abstract][Full Text] [Related]
18. [Antimicrobial drug therapy and microbial sensitivity tests: general concept of antibiotics].
Miyazakin S; Yamaguchi K
Rinsho Byori; 1997 Jul; Suppl 105():162-73. PubMed ID: 9379536
[No Abstract] [Full Text] [Related]
19. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2000)].
Shimada K; Terai T; Igari J; Inoue H; Nakadate T; Oguri T; Suwabe A; Obata R; Ikemoto H; Ohno I; Okada S; Hayashi K; Mori T; Nakano K; Arakawa M; Gejyo F; Igarashi K; Yokouchi H; Okada M; Ito A; Sumitomo M; Aoki N; Matsushima T; Niki Y; Kitamura N; Suga M; Suzuki Y; Karasawa Y; Tosaka M; Nakata K; Nakatani T; Kohno S; Tomono K; Miyazaki Y; Inagawa H; Hirakata Y; Aoki S; Matsuda J; Kudo K; Kobayashi N; Kinoshita T; Konosaki H; Nasu M; Nagai H; Kobayashi H; Kawai S; Takayasu S; Hiramatsu K; Nakano T
Jpn J Antibiot; 2002 Oct; 55(5):537-67. PubMed ID: 12532637
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
Dowzicky MJ
Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
